Lampalizumab

Drug Profile

Lampalizumab

Alternative Names: Anti-complement Factor D antibody; Anti-factor D; Anti-factor D Fab; FCFD4514S; RG7417; TNX-234

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Tanox
  • Developer Genentech
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Complement factor D inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dry age-related macular degeneration

Most Recent Events

  • 01 Jul 2016 Roche initiates a phase III extension trial for Dry age-related macular degeneration in USA (NCT02745119)
  • 21 Apr 2016 Roche plans a phase III extension trial for Dry age-related macular degeneration in USA (NCT02745119)
  • 10 Nov 2015 Lampalizumab receives Fast Track designation for Dry age-related macular degeneration [Intravitreous,Injection] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top